Imprint Wealth LLC Has $116,000 Position in Humacyte, Inc. (NASDAQ:HUMA)

Imprint Wealth LLC lessened its holdings in shares of Humacyte, Inc. (NASDAQ:HUMA) by 15.7% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 39,703 shares of the company’s stock after selling 7,369 shares during the quarter. Imprint Wealth LLC’s holdings in Humacyte were worth $116,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in HUMA. Advisor Group Holdings Inc. raised its position in Humacyte by 24.6% during the first quarter. Advisor Group Holdings Inc. now owns 25,020 shares of the company’s stock valued at $177,000 after acquiring an additional 4,946 shares in the last quarter. Swiss National Bank raised its position in shares of Humacyte by 7.4% in the first quarter. Swiss National Bank now owns 121,800 shares of the company’s stock valued at $860,000 after purchasing an additional 8,400 shares during the period. Bank of New York Mellon Corp bought a new position in shares of Humacyte in the first quarter valued at approximately $188,000. Citigroup Inc. raised its position in shares of Humacyte by 191.7% in the first quarter. Citigroup Inc. now owns 11,859 shares of the company’s stock valued at $84,000 after purchasing an additional 7,793 shares during the period. Finally, BlackRock Inc. raised its position in shares of Humacyte by 12.6% in the first quarter. BlackRock Inc. now owns 1,577,919 shares of the company’s stock valued at $11,140,000 after purchasing an additional 176,846 shares during the period. Institutional investors own 44.71% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently commented on HUMA. Benchmark reissued a “buy” rating and issued a $15.00 price target on shares of Humacyte in a research report on Monday, March 25th. Piper Sandler reaffirmed a “neutral” rating and set a $4.00 target price on shares of Humacyte in a research report on Tuesday, March 26th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $7.00 target price on shares of Humacyte in a research report on Monday, April 1st.

Humacyte Trading Up 6.6 %

Shares of HUMA stock opened at $3.06 on Wednesday. Humacyte, Inc. has a 1 year low of $1.96 and a 1 year high of $5.60. The company has a current ratio of 4.52, a quick ratio of 4.52 and a debt-to-equity ratio of 1.20. The firm’s fifty day simple moving average is $3.52 and its 200 day simple moving average is $2.97. The firm has a market capitalization of $364.38 million, a P/E ratio of -2.86 and a beta of 1.46.

Humacyte (NASDAQ:HUMA) last announced its quarterly earnings results on Friday, March 22nd. The company reported ($0.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.01. During the same quarter in the prior year, the business posted ($0.21) earnings per share. As a group, sell-side analysts predict that Humacyte, Inc. will post -0.9 EPS for the current year.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs).